{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-016847","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.926355+00:00","generated_at":"2026-06-22T03:29:31.662584+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Coherus Q3 net loss widens to $86.7M on 45% revenue decline; CIMERLI projected >$100M in 2023","bullets":["Q3 2022 net revenue $45.4M (down from $82.5M YoY); net loss $86.7M ($1.11 loss per share).","GAAP EPS loss $1.11 vs $0.49 loss YoY; non-GAAP EPS loss $0.96 vs $0.34 loss.","CIMERLI launched Oct 3, 2022; 2023 net sales projected >$100M; leading biosimilar market share.","Toripalimab BLA target action date Dec 23, 2022; FDA inspections hindered by COVID travel restrictions.","Targeting profitability in 2024; planning 2023 launches of YUSIMRY, toripalimab, UDENYCA OBI."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-016847","json":"https://secwatch.observer/filing/0001558370-22-016847.json","markdown":"https://secwatch.observer/filing/0001558370-22-016847.md","text":"https://secwatch.observer/filing/0001558370-22-016847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837022016847/0001558370-22-016847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837022016847/chrs-20221108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:29:31.662584+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79fac972d2bee1fce38e11f6853089c418995790","claim":"Coherus Oncology, Inc. reported third quarter ended September 30, 2022 results: revenue $45.4 million, net income Net loss of $86.7 million, or $(1.11) per share, EPS $(1.11) per share.","evidence_excerpt":"Net revenue, consisting primarily of net sales of UDENYCA®, was $45.4 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837022016847/0001558370-22-016847-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$45.4 million"},{"label":"Net income","value":"Net loss of $86.7 million, or $(1.11) per share"},{"label":"EPS","value":"$(1.11) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}